Sivia Capital Partners LLC Buys 3,081 Shares of Illumina, Inc. $ILMN

Sivia Capital Partners LLC lifted its stake in Illumina, Inc. (NASDAQ:ILMN) by 40.4% in the fourth quarter, Holdings Channel.com reports. The fund owned 10,714 shares of the life sciences company’s stock after purchasing an additional 3,081 shares during the period. Sivia Capital Partners LLC’s holdings in Illumina were worth $1,405,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently made changes to their positions in the company. Elyxium Wealth LLC bought a new position in shares of Illumina in the fourth quarter worth $25,000. Creative Capital Management Investments LLC boosted its holdings in shares of Illumina by 160.0% in the fourth quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock worth $26,000 after acquiring an additional 120 shares during the period. Board of the Pension Protection Fund bought a new position in shares of Illumina in the fourth quarter worth $26,000. TD Waterhouse Canada Inc. bought a new position in shares of Illumina in the fourth quarter worth $26,000. Finally, Laurel Wealth Advisors LLC bought a new position in shares of Illumina in the fourth quarter worth $26,000. 89.42% of the stock is owned by institutional investors.

More Illumina News

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Guggenheim raised its price target on Illumina to $180 from $170 and reiterated a Buy rating, reflecting optimism about clinical sequencing momentum, consumables pricing, and the company’s pipeline. Article
• Positive Sentiment: Integrated DNA Technologies expanded its collaboration with Illumina, linking xGen FFPE and cfDNA workflows to DRAGEN and Connected Insights, which could deepen Illumina’s role in oncology research and support software adoption. Article
• Positive Sentiment: Recent commentary highlighted Illumina’s better execution, stronger NovaSeq X adoption, and higher full-year 2026 guidance, which has helped extend the stock’s rally. Article
• Neutral Sentiment: Illumina reported small insider sales, including a routine Rule 10b5-1 sale by the chief accounting officer, which is not unusual but adds to scrutiny around insider activity. SEC filing
• Negative Sentiment: Director Keith A. Meister sold a large block of shares in multiple transactions, which could weigh on sentiment despite no direct sign of operational weakness. SEC filing

Insiders Place Their Bets

In other Illumina news, insider Scott M. Davies sold 615 shares of the firm’s stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $160.00, for a total transaction of $98,400.00. Following the sale, the insider owned 21,568 shares in the company, valued at $3,450,880. This trade represents a 2.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Christensen Jakob Wedel sold 700 shares of the firm’s stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $139.04, for a total value of $97,328.00. Following the sale, the senior vice president owned 15,056 shares in the company, valued at $2,093,386.24. The trade was a 4.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 1,002,371 shares of company stock worth $155,472,900. 2.90% of the stock is currently owned by corporate insiders.

Illumina Trading Up 5.2%

Shares of ILMN stock opened at $170.93 on Thursday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.36 and a current ratio of 1.75. Illumina, Inc. has a 52-week low of $81.75 and a 52-week high of $172.49. The company has a market capitalization of $25.86 billion, a PE ratio of 31.08, a price-to-earnings-growth ratio of 2.69 and a beta of 1.50. The business’s fifty day moving average is $136.19 and its 200 day moving average is $133.03.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.05 by $0.10. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The company had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.07 billion. During the same quarter last year, the business posted $0.97 earnings per share. The firm’s revenue was up 4.8% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. On average, equities research analysts anticipate that Illumina, Inc. will post 5.2 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently commented on ILMN shares. UBS Group reaffirmed a “neutral” rating and issued a $135.00 price target on shares of Illumina in a report on Friday, February 6th. Robert W. Baird set a $137.00 price target on Illumina in a report on Friday, February 6th. Evercore reaffirmed an “outperform” rating on shares of Illumina in a report on Friday, May 1st. Daiwa Securities Group raised Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price target for the company in a report on Thursday, May 14th. Finally, Barclays increased their price objective on Illumina from $110.00 to $122.00 and gave the stock an “underweight” rating in a research report on Friday, May 1st. Seven analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $138.38.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.